top of page

The Insurable, Secure

Healthcare Platform

Architecting the Future of Pharmacovigilance:
Inside Clintrue’s Next-Generation Neuro-Symbolic Safety Engine 

Neuro-Symbolic AI for Pharmacovigilance | Clintrue

October 10th, 2026

​

At Vereda Holdings, Inc., we recognize a critical inflection point in healthcare AI: the complexity of modern therapeutics and the "garbage-in" crisis of unstructured clinical data demand a radical shift in patient safety. Probabilistic "black-box" Large Language Models are fundamentally incompatible with the uncompromising demands of regulatory governance and clinical decision-making.


Today we are proud to unveil the technical blueprint for the next-generation Clintrue Safety Search App—an enterprise-grade, agentic Pharmacovigilance (PV) and Clinical Decision Support (CDS) platform.


Recently submitted for the U.S. Food and Drug Administration TEMPO Pilot Phase II review and designed to support the Centers for Medicare & Medicaid Services ACCESS Model’s Cardio-Kidney-Metabolic (CKM) tracks, Clintrue acts as a proactive safety firewall for high-complexity patient cohorts.


Here is how we are engineering the ultimate liability shield for complex clinical care:


The Core Paradigm: Neuro-Symbolic AI & "Glass Box" Transparency

To eradicate clinical noise and guarantee 100% audit-ready compliance, Clintrue enforces a rigid separation of concerns:


  • The Firewalled LLM Layer: Generative AI is strictly restricted to Natural Language Processing (NLP) and Named Entity Recognition (NER). Operating behind a "verbatim-span guardrail," our models extract exact substrings from source documents without ever generating or inferring clinical meaning—eliminating hallucination risks.


  • The Deterministic Safety Engine: All clinical safety logic is executed by a verifiable, non-generative Directed Acyclic Graph (DAG) engine. Every flagged risk generates a machine-readable computational graph, tracing the algorithmic rationale directly back to verbatim source texts.


"Bilateral Logic" & Proactive Risk Mitigation

Clintrue utilizes a unique Bilateral Logic architecture that continuously weighs a therapy’s foundational trial efficacy against a patient's evolving physiological markers (eGFR, BP, HbA1c, etc.). By simultaneously matching live patient data against the exclusion criteria of over 590,000 clinical trials from resources like ClinicalTrials.gov, the engine identifies profound "Off-Evidence" risks. This proactively intercepts Adverse Drug Events (ADEs) before a prescription is finalized, ensuring patients maintain the physiological stability necessary to achieve sustained 12-month Outcome-Aligned Payment (OAP) targets.


Agentic AI, Temporal Signal Detection & Compute Power

Moving beyond legacy statistical methods, Clintrue leverages Continuous-Time Sequence Modeling to natively map irregular temporal gaps in longitudinal EHR data. To handle the immense computational intensity of High-Dimensional Vector Matching across global trial data, Clintrue leverages NVIDIA Orin IGX modules, proudly accelerating our infrastructure through our partnership in the NVIDIA Inception program.


Enterprise Integration & Continuous MLOps Governance

Designed for seamless SMART on HL7 International (FHIR) interoperability with enterprise EHR leaders like Epic and Oracle Health, Clintrue fully embraces its classification as Software as a Medical Device (SaMD). Built on Amazon Web Services (AWS) leveraging Amazon SageMaker for continuous drift detection and developed under a rigid ISO 13485 Quality Management System, the platform features automated CAPA integration compliant with 21 CFR Part 820—positioning us to confidently pursue FDA De Novo or 510(k) clearance.


🔒 Proprietary Innovation & Global IP Protection

Clintrue’s neuro-symbolic framework and core "Bilateral Logic" architecture represent a defensible leap forward in clinical AI. To secure our market position, this proprietary technology is actively protected by a comprehensive portfolio of domestic and international patent filings, ensuring a secure commercial moat as we scale enterprise deployments globally.


The era of reactive pharmacovigilance and opaque AI is over. We are bridging the gap between raw, unstructured data and actionable, deterministic safety intelligence.

bottom of page